Cycle length: 21 days, for a maximum of six cycles. | |||
Drug | Dose and route | Administration | Given on days |
Carboplatin | AUC* = 5 mg/mL × min IV | Dilute in 250 mL NS¶ and administer over 30 minutes. | Day 1 |
Etoposide | 100 mg/m2 IV | Dilute in 500 mL NS or D5W¶ to final concentration <0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur. | Days 1, 2, and 3 |
Pretreatment considerations: | |||
Emesis risk |
| ||
Vesicant/irritant properties |
| ||
Infection prophylaxis |
| ||
Dose adjustment for baseline liver or kidney dysfunction |
| ||
Monitoring parameters: | |||
| |||
| |||
Suggested dose modifications for toxicity: | |||
Myelotoxicity |
| ||
Nonhematologic toxicity |
| ||
Hepatotoxicity |
| ||
Nephrotoxicity |
| ||
If there is a change in body weight of at least 10%, doses should be recalculated. |
ANC: absolute neutrophil count; AUC: area under the concentration × time curve; CBC: complete blood count; D5W: 5% dextrose in water; GFR: glomerular filtration rate; IV: intravenous; NCCN: National Comprehensive Cancer Network; NS: normal saline.
* AUC is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topics on dosing of anticancer agents in adults.
¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).
Δ Consensus-based guidelines from the NCCN classify higher carboplatin doses (AUC ≥4) as highly emetogenic; by contrast, the American Society of Clinical Oncology and the Multinational Association for Supportive Care in Cancer guidelines consider all carboplatin doses to be moderately emetogenic. Although many institutions classify carboplatin-containing regimens as moderately emetogenic, a benefit for adding a neurokinin 1 receptor antagonist on day 1 has been shown in many studies; additional prophylaxis beyond day 1 for delayed emesis is not needed for most patients. Refer to UpToDate topics on prevention and treatment of chemotherapy-induced nausea and vomiting in adults.
Do you want to add Medilib to your home screen?